Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.34 |
| ▸ | ATRIP | Q8WXE1 | 3/20 | 0.34 |
| ▸ | CCNC | P24863 | 2/20 | 0.32 |
| ▸ | CDK8 | P49336 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4B | O94953 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.30 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.30 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022428 | 0.84 | HCAR2 (0.37) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL1299475 | 0.79 | JMJD6 (0.30) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL29696567 | 0.74 | GDA (0.39) | CCNCCDK8KDM4AKDM4BKDM5C | |
| SCHEMBL60386 | 0.72 | KDM4A (0.33) | ATRATRIPKDM4AKDM4BKDM5C | |
| SCHEMBL1298647 | 0.72 | KDM4A (0.33) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL2554279 | 0.71 | PDPK1 (0.34) | — | |
| SCHEMBL14485456 | 0.68 | KDM4A (0.33) | KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL27510684 | 0.68 | KDM4A (0.33) | ATRATRIPKDM4AKDM4BKDM5C | |
| SCHEMBL22273390 | 0.67 | MAP2K3 (0.32) | LCKMAP2K3MAP2K6BTKMAP3K19 | |
| SCHEMBL30808869 | 0.66 | CCNC (0.55) | CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590335-A4 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-03-08 | — | — | EP | claimed |
| US-20060041124-A1 | Process for preparing pyrrolotriazine kinase inhibitors | CHEN BANG-CHI | 2006-02-23 | — | — | US | claimed |
| EP-1590335-A2 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-11-02 | — | — | EP | claimed |
| WO-2004072030-A2 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | claimed |
| US-20040157846-A1 | Process for preparing pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-12 | — | — | US | claimed |
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1503996-B1 | ARYL KETONE PYRROLO-TRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7314876-B2 | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1503996-A4 | ARYL KETONE PYRROLO-TRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-05-17 | — | — | EP | disclosed |
| US-7034151-B2 | 1,4-dihydro-4-oxo-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylates; novel approach to the formation of the bicyclic heterocyclic ring system | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1590335-A4 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1363910-B1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2004072030-A2 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157846-A1 | Process for preparing pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-12 | — | — | US | disclosed |
| US-6670357-B2 | Antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030232831-A1 | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1363910-A2 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003091229-A1 | ARYL KETONE PYRROLO-TRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| WO-2002040486-A2 | METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | MAPK1, MAPK3, MAPK6 | ATR 1175/4885ATRIP 3988/4885CCNC 1782/4885 |
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K5, MAPK1, MAPKAPK5 | ATR 1672/4885ATRIP 4089/4885CCNC 1773/4885 |
| US-20030232831-A1 | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors | MAPK1, MAPK3, MAPK15 | ATR 360/4885ATRIP 2244/4885CCNC 744/4885 |
| US-20040157846-A1 | Process for preparing pyrrolotriazine kinase inhibitors | MAP3K15, MAP4K2, MAP3K5 | ATR 487/4885ATRIP 877/4885CCNC 517/4885 |
| US-20060041124-A1 | Process for preparing pyrrolotriazine kinase inhibitors | MAP3K15, MAP4K2, MAP3K5 | ATR 487/4885ATRIP 877/4885CCNC 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.